#South Korea #Seoul #Cancer Treatment #Hyundai ADM #OTX-M

Hyundai ADM Bio Innovations in Cancer Treatment

Hyundai ADM Bio, led by Co-CEOs Taek-Sung Kim and Kwang-Hee Kim, recently revealed groundbreaking results regarding its anti-cancer medication OTX-M during the Biotech Showcase 2025. This oral drug, built upon the injectable chemotherapy docetaxel, offers a novel shift from traditional intravenous methods to a more patient-centered approach.

Introduction of OTX-M

OTX-M utilizes an innovative organic-inorganic hybrid drug delivery system developed by Hyundai ADM's partner company, CNPharm. Differing from existing oral anti-cancer treatments, which often faced challenges concerning drug-drug interactions, OTX-M boosts docetaxel's bioavailability by an astonishing 1,600 times, without the use of metabolic inhibitors.

Study Findings and Optimal Dosage

A thorough preclinical study evaluated various dosage levels and frequencies. Low doses administered twice daily reached a tumor inhibition rate of 61.4%, while moderate doses taken once daily showed even better results with an 82.83% inhibition rate. High doses, although peaking at a remarkable 92.81% tumor inhibition when taken four times per week, came with significant weight loss and side effects, underscoring the need for careful dosage evaluation. The optimal approach identified is a moderate dose taken once daily, presenting a favorable balance of effectiveness and safety.

Economic and Practical Implications

The implications of OTX-M extend beyond clinical efficiency. Research from Rutgers University and Chung-Ang University indicates that oral therapies can cut treatment costs by nearly 60% compared to traditional injectables. This affordability makes OTX-M an excellent option for regions with limited healthcare infrastructures. Importantly, the self-administered nature of OTX-M alleviates burdens on healthcare facilities, providing a more convenient treatment pathway for patients.

Recognition from Industry Leaders

The developers at the Biotech Showcase acknowledged the challenges in converting taxane-based drugs into oral formats. OTX-M's success in resolving previous concerns about bioavailability and safety sets it apart as a potential game-changer in the oncology treatment space. As stated by one industry expert, it addresses significant barriers that have hindered the advancement of oral chemotherapy.

Hyundai ADM's Vision for Future Treatments

The CEO, Taek-Sung Kim, reinforced the company's commitment to transforming chemotherapy by developing OTX-M as a convenient, low-side-effect alternative. Their vision is to treat cancer not just as a terminal illness but as a manageable condition similar to chronic disease management.

This shift is designed to enhance both living standards and experiences for cancer patients globally, laying the groundwork for OTX-M to establish itself in the worldwide pharmaceutical market following successful clinical trials in the United States.

About Hyundai ADM Bio

Hyundai ADM Bio operates under the umbrella of Hyundai Bioscience, focusing on the creation of anti-cancer medications while also functioning as a Clinical Research Organization in South Korea. The company is listed on the KOSDAQ stock exchange, symbol 187660. Established in 2000, Hyundai Bioscience continues to innovate, seeking to repurpose existing drugs and apply its advanced drug delivery systems to improve therapeutic outcomes for patients.